SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Mawson Infrastructure Group, Inc. engages in the provision of digital asset infrastructure services. The company was founded on February 10, 2012 and is headquartered in Midland, PA.

Mawson Infrastructure Group Inc

Mawson Infrastructure Group ($MIGI) is trending amid significant price volatility and trading halts, with traders actively discussing its low float and short squeeze potential. Community members are focused on the company's presentation at the Emerging Growth Conference and speculating about potential catalysts and operational updates. Price targets among traders range widely, with some eyeing substantial gains if momentum and news align.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is trending due to its upcoming AI and Autonomy Day, where the company is expected to showcase its in-house software and autonomous driving technology; this has sparked both excitement and skepticism within the investment community. Discussions range from Rivian's potential to challenge Tesla in the EV market with its AI advancements, to concerns about the company's profitability and ability to execute its long-term vision amid slowing EV demand.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle's stock is trending downwards as investors react to earnings and significant capital expenditure plans related to AI, sparking concerns about the company's debt and future profitability. Community discussions revolve around whether Oracle is overspending in its AI endeavors and if its leadership is effectively navigating the company's transition. Analysts are adjusting their price targets, reflecting the uncertainty surrounding Oracle's financial strategy and its position in the evolving tech landscape.

Black Titan Corp. was formed for the purpose of effecting a merger between Titan Pharmaceuticals Inc. and TalenTec Sdn Bhd. It intends to explore and identify viable business opportunities. The company was founded on July 11, 2024 and is headquartered in Petaling Jaya, Malaysia.

Black Titan Corp.

Black Titan Corp ($BTTC) is surging as investors discuss its new digital asset strategy (DAT+) framework, specifically its focus on utility and risk management within decentralized finance. Community members are actively trading the stock, anticipating further news and potential short squeezes, while also drawing comparisons to other high-flying tickers. The stock's low float and connection to the crypto sector are contributing to heightened interest and volatility.

TMC the metals co., Inc. is a deep-sea minerals exploration company focused on the collection and processing of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone in the Pacific Ocean (CCZ). These nodules contain high grades of four metals (nickel, copper, cobalt, manganese) which can be used as (i) feedstock for battery cathode precursors (nickel, cobalt and manganese sulfates, or intermediate nickel-copper-cobalt matte) for electric vehicles (EV) and renewable energy storage markets, (ii) copper cathode for EV wiring, energy transmission and other applications and (iii) manganese silicate for manganese alloy production required for steel production. The company was founded in 2021 and is headquartered in Vancouver, Canada.

TMC the metals company Inc

TMC is trending as investors discuss the potential for news related to critical mineral supply chains and government support, with some anticipating a squeeze on short positions. Community members are debating the timeline for permits and production, as well as the impact of recent conferences and events. Bullish sentiment appears to be building despite some volatility, with many citing the company's long-term potential in the EV materials sector.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and the FC SAN business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom is trending as investors anticipate upcoming earnings, with many expecting a strong report driven by AI and custom chip deals with major companies like Google and Microsoft. Bullish sentiment is fueled by analyst upgrades and the potential for significant revenue growth in the AI sector. The community is closely watching whether Broadcom can maintain its momentum and justify its valuation amid high expectations.

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Lab is trending as investors discuss its potential as an alternative to SpaceX, especially with buzz around SpaceX's possible IPO. Community members are pointing to the stock's recent gains and anticipating further upside, while also discussing upcoming catalysts such as Neutron readiness and government contracts. Some traders are highlighting the space sector's overall momentum and potential growth.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. It operates through the United States and International geographical segments. The firm offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

Trade Desk ($TTD) is trending as the stock price hovers near 52-week lows, sparking debates on whether it's a value trap, a takeover target, or simply experiencing tax-loss selling. Community discussions revolve around the possibility of a short squeeze, the company's growth prospects amid competition from larger players, and frustration with management's strategy.

Gemini Space Station, Inc. is a holding company, which offers a mobile and web based crypto asset exchange platform, proprietary wallet infrastructure and custody solutions, over-the-counter trading solutions tailored to institutions and professionals, a digital art auction platform, a proprietary United States dollar backed stablecoin, and a credit card product that offers crypto asset rewards on customer purchases. The company was founded by Tyler Winklevoss and Cameron Winklevoss in 2014 and is headquartered in New York, NY.

Gemini Space Station Inc. - Ordinary Shares- Class A

Gemini Space Station

GEMI is trending as investors discuss its potential following the CFTC's approval of its Designated Contract Market (DCM) license, allowing the company to offer regulated prediction markets in the U.S. The community believes this license could significantly increase the company's valuation, drawing comparisons to competitors in the prediction market space. Some are pointing to the potential for a short squeeze, citing high short interest and limited shares available.

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

SLV is trending as silver spot prices surge, sparking excitement about potential triple-digit prices and comparisons to previous precious metal rallies. Community discussions focus on the interplay between physical silver demand and paper trading, with some highlighting supply deficits and potential for a short squeeze. Bullish sentiment is fueled by expectations of continued gains in the silver market amid a weaker dollar.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Platform Technologies Drive $211B Surge in Precision Cancer Treatment

Platform Technologies Drive $211B Surge in Precision Cancer Treatment Platform Technologies Drive $211B Surge in Precision Cancer Treatment PR Newswire VANCOUVER, BC, Dec. 11, 2025 Issued on behalf...

Stocks & Markets Podcast: Biotech CEO reveals the science of humane cancer treatment

This article is based on TheStreet's Stock & Markets Podcast. Hosted by Chris Versace, the veteran Wall Street investor and lead portfolio manager for TheStreet Pro, the weekly podcasts are available...

Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points

Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points PR Newswire VANCOUVER, BC, Dec...

Natural Killer Cell Therapies Lead $254B Immunotherapy Market Transformation

Natural Killer Cell Therapies Lead $254B Immunotherapy Market Transformation Natural Killer Cell Therapies Lead $254B Immunotherapy Market Transformation PR Newswire VANCOUVER, BC, Oct. 17, 2025...

Precision Oncology Approaches Drive $312B Market Transformation

Precision Oncology Approaches Drive $312B Market Transformation Precision Oncology Approaches Drive $312B Market Transformation PR Newswire VANCOUVER, Oct. 17, 2025 USA News Group News Commentary...

Next-Generation Targeted Therapies Reshape Precision Oncology Landscape

Next-Generation Targeted Therapies Reshape Precision Oncology Landscape Next-Generation Targeted Therapies Reshape Precision Oncology Landscape PR Newswire VANCOUVER, BC, Oct. 15, 2025 USA News Group...

Cellular Immunotherapy Breakthroughs Fuel $370 Billion Market Surge

Cellular Immunotherapy Breakthroughs Fuel $370 Billion Market Surge Cellular Immunotherapy Breakthroughs Fuel $370 Billion Market Surge PR Newswire VANCOUVER, BC, Oct. 15, 2025 Equity Insider News...

Shares of GT Biopharma had their best trading day in more than nine months after the company shared encouraging progress from its ongoing Phase 1 trial of GTB-3650, an experimental treatment for patients with relapsed or refractory CD33-positive blood cancers.The stock jumped 43.7% to $1.08 at Wednesday’s close, before slipping 10.5% in after-hours trading.The clinical-stage biotech company said enrollment in the study’s dose-escalation groups is progressing smoothly and remains “well on track.” Both patients in Cohort 3 have now begun treatment, with no signs of dose-limiting toxicities or tolerability issues so far.&nbsp;The company added that the first patient in Cohort 3 has shown “promising evidence of immune activation,” matching the levels of activity seen in patients from the two earlier, lower-dose groups.GT Biopharma's trial will evaluate the safety, pharmacokinetics/pharmacodynamics of GTB-3650, and evidence of immune activation. GTB-3650 will use the company's TriKE platform to recruit natural killer (NK) cells to fight cancer.The Phase 1 study can enroll up to 14 patients, with two people in each of seven planned dosing groups. The lowest dose starts at 1.25 micrograms per kilogram per day and could go up to 100 micrograms per kilogram per day in the highest group. Each patient will take the drug in two-week treatment cycles, with two weeks on therapy followed by two weeks off, for as long as four months if they continue to show signs of clinical benefit.If Cohort 3 is dosed without any problems, GT Biopharma anticipates dosing the first patient in Cohort 4 by the end of 2025. The dose level can be increased further if warranted. The company expects to provide an update on additional data by the end of 2025 and in the first quarter of 2026 as it moves to the higher dose levels in the trial that may yield more robust therapeutic effects.On Stocktwits, retail sentiment for GT Biopharma was ‘extremely bullish’ amid a 2,933% surge in 24-hour message volume.One user said that GT Biopharma shares appeared to be gaining strong upward momentum and could move toward double-digit levels.&nbsp;<stembedurl>https://stocktwits.com/Illbeyourhuckleberree/message/631516421</stembedurl>Another user commented that the company’s cancer therapy showed significant promise, with the potential for substantial long-term returns.<stembedurl>https://stocktwits.com/Djdanny/message/631566315</stembedurl><a href="https://stocktwits.com/symbol/GTBP">GT Biopharma’s stock</a> has declined 65% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

GT Biopharma’s stock (GTBP) has declined 65% so far in 2025. (Photo credit: Getty Images)

GT Biopharma Stock Logs Best Session In Over 9 Months On Promising Cancer Trial Data; Retail Eyes Double-Digit Rally

The biotech firm reported smooth progress in its Phase 1 trial of GTB-3650, with no safety issues and early signs of immune activation in the latest dosing group. 

Equity

Shares of GT Biopharma, Inc. surged more than 21% on Tuesday before slipping after-hours as investors reacted to the company's unexpected shift in its financing strategy.&nbsp;The announcement sent 24-hour message volume on Stocktwits skyrocketing by 18,700%, marking the highest spike among biotech stocks, with trading volume more than doubling from its daily average.The company said it had withdrawn its earlier Form S-1 registration, initially filed with the SEC in December, which sought approval for an automatic mixed securities shelf offering.&nbsp;The filing had not yet been declared effective, and no securities had been sold under the proposed offering.&nbsp;Instead, GT Biopharma opted for a direct warrant exercise agreement, securing immediate funds while offering new unregistered warrants to investors.Under the new arrangement, the company entered into definitive agreements to exercise existing warrants to purchase 302,069 shares of common stock, with an exercise price of $4.35 per share.&nbsp;The move is expected to generate approximately $700,000 in gross proceeds before deducting placement agent fees and offering expenses.The offering is anticipated to close by Thursday, with proceeds earmarked for working capital and general corporate purposes.On Stocktwits, retail investors' reactions were mostly positive to the company's financing shift.&nbsp;One user described the move as "going in the right direction."&nbsp;<stembedurl>https://stocktwits.com/Rassy40/message/605686808</stembedurl>Another pointed out that short sellers had expected dilution due to the S-1 registration, but they may now be forced to cover with the offering canceled.&nbsp;<stembedurl>https://stocktwits.com/Annet_why_net/message/605691704</stembedurl>However, some traders indicated they were still waiting for a more attractive entry point.Short interest on GTBP shares has jumped from 0.6% at the start of the year to 8.8% at the end of last week, per Koyfin data.Beyond the financing development, Roth MKM remains optimistic about GT Biopharma's clinical pipeline.&nbsp;The research firm expects the company to release initial data later this year from its Phase 1 trial evaluating GTB-3650, its therapy targeting CD33-expressing hematologic malignancies, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome.GT Biopharma ended 2024 with approximately $4 million in cash, which Roth MKM estimates is sufficient to fund operations into the second quarter of this year.&nbsp;The research firm maintained a 'Buy' rating on the stock, with an $11 price target, implying a potential fivefold increase from current levels.The company's stock has lost more than 17% year-to-date.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stockbroker analyzing financial stock market with reflection on eyeglasses. Photo via Westend61 on Getty Images

GT Biopharma Retail Chatter Soars Most Among Biotechs After Financing Strategy Tweak

The company said it had withdrawn its earlier Form S-1 registration, initially filed with the SEC in December, which sought approval for an automatic mixed securities shelf offering.

GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of the immuno-oncology therapeutic products based proprietary TriKE NK cell engager platform. The TriKE platform is designed to harness and enhance the cancer killing abilities of a patient's immune system natural killer cells (NK cells). Its product, GTB-3550, is initially developed for the treatment of AML and MDS, and other CD33+ hematologic cancers. GT Biopharma has a worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE technology. The company was founded in 1965 and is headquartered in San Francisco, CA.

GT Biopharma Inc

Bullish: S&P grinds higher

Choppy but up: buy dips

Sideways: fade the move

Bearish: this rally falls off

The Federal Reserve just announced a 0.25 percentage point interest rate cut at its December 10, 2025 meeting.​ Share your outlook on how the latest Federal Reserve interest rate cut will impact stocks and the S&P 500 over the next month.

How do you think today’s Fed rate cut impacts stocks over the next month?

GTBP
GT Biopharma Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest GTBP News

GTBPGT Biopharma Inc